Rapport, a J&J Neuroscience Spinout, Prepares for Summer IPO as the First Biotech of the Season

1. Rapport, a neuroscience-focused biotech company, is set to be the first biotech firm to announce its initial public offering (IPO) plans for the summer.
2. The company is a spinout from Johnson & Johnson (J&J), a multinational corporation specializing in pharmaceuticals, medical devices, and consumer packaged goods.
3. Rapport was founded in partnership with Third Rock, a leading healthcare venture firm.
4. The company's focus on neuroscience research and development makes it a unique player in the biotech industry.
5. The announcement of Rapport's IPO plans marks a significant milestone in the company's growth and development.
6. The IPO is expected to provide Rapport with the necessary capital to further its research and development efforts in the field of neuroscience.
7. The move could also set a precedent for other biotech firms considering IPOs in the near future.